Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC

Leukemia. 2021 Jan;35(1):294. doi: 10.1038/s41375-020-01071-7.

I Tirado-Gonzalez^#¹, E Czlonka^#¹, A Nevmerzhitskaya^#¹, D Soetopo¹, E Bergonzani¹, A Mahmoud¹, A Contreras¹, I Jeremias^{2

3}, U Platzbecker^{4

5}, J P Bourquin⁶, U Kloz⁶, F Van der Hoeven⁷, H Medyouf^{8

9

10}

¹ Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
² Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Münich, German Center for Environmental Health (HMGU), Munich, Germany.
³ German Cancer Consortium, DKTK Partner Site Munich, Heidelberg, Germany.
⁴ University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
⁵ German Cancer Consortium, DKTK Partner Site Dresden, Heidelberg, Germany.
⁶ Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland.
⁷ Transgenic Service, German Cancer Research Center, Heidelberg, Germany.
⁸ Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany. [email protected].
⁹ German Cancer Consortium, DKTK Partner Site Frankfurt/Mainz, Heidelberg, Germany. [email protected].
¹⁰ Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty, University of Heidelberg, Mannheim, Germany. [email protected].

^# Contributed equally.

No abstract available

Publication types